Baird analyst David Rescott raised the firm’s price target on Merit Medical (MMSI) to $103 from $102 and keeps an Outperform rating on the shares. The firm updated its model following impressive Q3 results but where volatility remains ahead of its TPT update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $109 from $105 at Piper Sandler
- Cautious Hold Rating for Merit Medical Systems Amid Strong Q3 and Transitional Challenges
- Merit Medical Systems: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Merit Medical Reports Strong Q3 2025 Growth
- Merit Medical Systems Reports Strong Q3 2025 Results